X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with WYETH LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs WYETH LTD - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB WYETH LTD DR. REDDYS LAB/
WYETH LTD
 
P/E (TTM) x 28.0 27.7 101.0% View Chart
P/BV x 2.9 5.3 53.9% View Chart
Dividend Yield % 1.0 1.3 77.1%  

Financials

 DR. REDDYS LAB   WYETH LTD
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-16
WYETH LTD
Mar-13
DR. REDDYS LAB/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs4,3831,044 419.7%   
Low Rs2,750818 336.2%   
Sales per share (Unadj.) Rs920.1298.6 308.2%  
Earnings per share (Unadj.) Rs126.157.2 220.3%  
Cash flow per share (Unadj.) Rs183.058.4 313.3%  
Dividends per share (Unadj.) Rs20.0017.00 117.6%  
Dividend yield (eoy) %0.61.8 30.7%  
Book value per share (Unadj.) Rs685.8249.5 274.9%  
Shares outstanding (eoy) m170.6122.72 750.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.93.1 124.3%   
Avg P/E ratio x28.316.3 173.9%  
P/CF ratio (eoy) x19.515.9 122.3%  
Price / Book Value ratio x5.23.7 139.3%  
Dividend payout %15.929.7 53.4%   
Avg Mkt Cap Rs m608,48121,157 2,876.0%   
No. of employees `00021.70.5 4,404.3%   
Total wages/salary Rs m31,874400 7,968.5%   
Avg. sales/employee Rs Th7,244.413,787.4 52.5%   
Avg. wages/employee Rs Th1,470.9813.0 180.9%   
Avg. net profit/employee Rs Th992.82,643.3 37.6%   
INCOME DATA
Net Sales Rs m156,9786,783 2,314.1%  
Other income Rs m2,693353 763.8%   
Total revenues Rs m159,6717,136 2,237.5%   
Gross profit Rs m34,5871,617 2,138.6%  
Depreciation Rs m9,70527 36,485.0%   
Interest Rs m8246 14,981.8%   
Profit before tax Rs m26,7511,938 1,380.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m5,237632 828.4%   
Profit after tax Rs m21,5141,301 1,654.3%  
Gross profit margin %22.023.8 92.4%  
Effective tax rate %19.632.6 60.0%   
Net profit margin %13.719.2 71.5%  
BALANCE SHEET DATA
Current assets Rs m118,2016,984 1,692.5%   
Current liabilities Rs m68,3682,056 3,325.5%   
Net working cap to sales %31.772.6 43.7%  
Current ratio x1.73.4 50.9%  
Inventory Days Days6099 60.4%  
Debtors Days Days9724 404.7%  
Net fixed assets Rs m72,265244 29,580.4%   
Share capital Rs m853227 375.4%   
"Free" reserves Rs m111,5485,441 2,050.2%   
Net worth Rs m117,0095,668 2,064.4%   
Long term debt Rs m10,69025 42,760.0%   
Total assets Rs m200,1047,901 2,532.6%  
Interest coverage x33.5353.3 9.5%   
Debt to equity ratio x0.10 2,071.3%  
Sales to assets ratio x0.80.9 91.4%   
Return on assets %11.216.5 67.5%  
Return on equity %18.422.9 80.1%  
Return on capital %21.634.0 63.4%  
Exports to sales %46.30.2 21,202.7%   
Imports to sales %9.036.3 24.6%   
Exports (fob) Rs m72,61815 490,662.2%   
Imports (cif) Rs m14,0502,465 569.9%   
Fx inflow Rs m75,40515 496,085.5%   
Fx outflow Rs m27,1152,677 1,012.8%   
Net fx Rs m48,290-2,662 -1,814.0%   
CASH FLOW
From Operations Rs m40,476923 4,384.3%  
From Investments Rs m-19,421317 -6,128.4%  
From Financial Activity Rs m-17,009-481 3,536.2%  
Net Cashflow Rs m4,046759 533.0%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 5.4 11.3 47.8%  
FIIs % 35.3 7.2 490.3%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 30.4 50.3%  
Shareholders   75,885 21,978 345.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  SUN PHARMA  SANOFI INDIA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Strong; Consumer Durables Stocks Drag(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are trading above the dotted line. Except stocks in the consumer durables sector.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 23, 2017 02:02 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS